Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

DNA methylation is interpreted by a family of methyl-CpG binding domain (MBD) proteins that repress transcription through recruitment of corepressors that modify chromatin. To compare in vivo binding of MeCP2 and MBD2, we analyzed immunoprecipitated chromatin from primary human cells. Genomic sites occupied by the two MBD proteins were mutually exclusive. As MeCP2 was unable to colonize sites vacated by depletion of MBD2, we tested the hypothesis that methyl-CpG alone is insufficient to direct MeCP2 binding. In vitro selection for MeCP2 bound DNA-enriched fragments containing A/T bases ([A/T] > or = 4) adjacent to methyl-CpG. [A/T] > or = 4 was found to be essential for high-affinity binding at selected sites and at known MeCP2 target regions in the Bdnf and Dlx6 genes. MBD2 binding, however, did not require an A/T run. The unexpected restriction of MeCP2 to a defined subset of methyl-CpG sites will facilitate identification of genomic targets that are relevant to Rett Syndrome.

Original publication

DOI

10.1016/j.molcel.2005.07.021

Type

Journal article

Journal

Mol Cell

Publication Date

02/09/2005

Volume

19

Pages

667 - 678

Keywords

Adenine, Base Sequence, Brain-Derived Neurotrophic Factor, Cell Line, Cell Line, Tumor, Chromosomal Proteins, Non-Histone, CpG Islands, DNA, DNA Methylation, DNA-Binding Proteins, Homeodomain Proteins, Humans, Methyl-CpG-Binding Protein 2, Mutation, Protein Binding, Repressor Proteins, Thymine